Turtle Creek Wealth Advisors LLC Buys New Holdings in Medtronic PLC $MDT

17 Oct 2025, 09:58 by Doug Wharley · The Cerbat Gem

Turtle Creek Wealth Advisors LLC bought a new stake in Medtronic PLC (NYSE:MDT – Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,377 shares of the medical technology company’s stock, valued at approximately $294,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in MDT. 1248 Management LLC bought a new stake in Medtronic in the 1st quarter valued at about $26,000. Columbia River Financial Group LLC bought a new stake in Medtronic during the 1st quarter worth approximately $28,000. Twin Tree Management LP bought a new stake in Medtronic during the 1st quarter worth approximately $29,000. Activest Wealth Management increased its holdings in Medtronic by 3,577.8% during the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after purchasing an additional 322 shares in the last quarter. Finally, Hughes Financial Services LLC bought a new stake in Medtronic during the 1st quarter worth approximately $32,000. 82.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

MDT has been the subject of a number of recent research reports. Evercore ISI boosted their price objective on Medtronic from $103.00 to $106.00 and gave the stock an “outperform” rating in a report on Tuesday, July 8th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a report on Wednesday, October 8th. The Goldman Sachs Group reduced their target price on Medtronic from $82.00 to $81.00 and set a “sell” rating for the company in a report on Wednesday, October 1st. Wells Fargo & Company upped their target price on Medtronic from $98.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, August 20th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Medtronic in a report on Friday, July 11th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and a consensus target price of $102.82.

Check Out Our Latest Stock Report on MDT

Insider Activity at Medtronic

In other news, Director William R. Jellison acquired 2,500 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The shares were acquired at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the purchase, the director owned 5,000 shares in the company, valued at approximately $461,850. This trade represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the transaction, the executive vice president owned 35,615 shares in the company, valued at approximately $3,261,621.70. The trade was a 19.46% decrease in their position. The disclosure for this sale can be found here. 0.26% of the stock is currently owned by corporate insiders.

Medtronic Stock Performance

MDT stock opened at $94.98 on Friday. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $99.37. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. The business has a 50 day moving average of $94.01 and a 200-day moving average of $88.93. The firm has a market cap of $121.83 billion, a PE ratio of 26.17, a P/E/G ratio of 2.51 and a beta of 0.78.

Medtronic (NYSE:MDT – Get Free Report) last posted its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, beating the consensus estimate of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The business had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. During the same quarter in the prior year, the business earned $1.23 earnings per share. Medtronic’s revenue for the quarter was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, sell-side analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 17th. Investors of record on Friday, September 26th will be paid a $0.71 dividend. The ex-dividend date is Friday, September 26th. This represents a $2.84 annualized dividend and a yield of 3.0%. Medtronic’s dividend payout ratio is presently 78.24%.

About Medtronic

(Free Report)

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.